Table 1

Characteristics of adults with CAP requiring hospitalisation or managed in the community

Pneumococcal group (n=59)Non-pneumococcal group (n=127)CAP cohort (n=186)
Demographics
 Age years79 (71 to 83)79 (73 to 85)79 (73 to 85)
 Male42 (71.2)79 (62.2)121 (65.1)
Reporting
 Hospital physicians38 (64.4)105 (82.7)143 (76.9)
 GPs21 (35.6)22 (17.3)43 (23.1)
 Any underlying comorbidity*
 Chronic heart disease28 (47.5)70 (55.1)98 (52.7)
 Chronic respiratory disease29 (49.2)52 (40.9)81 (43.6)
 Diabetes14 (23.7)32 (25.2)46 (24.7)
 Chronic kidney disease2 (3.4)9 (7.1)11 (5.9)
 Chronic liver disease2 (3.4)3 (2.4)5 (2.6)
 Malignancy04 (3.1)4 (2.1)
 Asplenia1 (1.7)1 (0.8)2 (1.1)
Status regarding receipt of pneumococcal vaccination†
 PCV135 (8.5)15 (11.8)20 (10.8)
 PPSV23 given <5 years prior to study enrolment20 (33.9)40 (31.5)60 (32.3)
Outcomes‡
 30-day mortality2 (3.4)2 (1.6)4 (2.2)
 Recovery with sequelae5 (8.5)20 (15.7)25 (13.4)
  • Data are number, median (IQR) or number (%).

  • *The groups were not mutually exclusive and therefore do not sum to 100%.

  • †For both vaccines, patients were considered to be vaccinated if they had received the vaccine at least 2 weeks before enrolment. Data were missing for four patients in the non-pneumococcal group. One patient had received a dose of PCV13 ≥1 year after receipt of a PPSV23 dose given <5 years prior to study enrolment.

  • ‡Data were missing for 20 patients in the pneumococcal group and 40 patients in the non-pneumococcal group.

  • CAP, community-acquired pneumonia; GPs, general practitioners; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.